Η φαρμακευτική πολιτική στην Ελλάδα (2010-2014) : πορεία ιδιωτικοποίησης και περιοριστικής διανομής
Pharmaceutical policies in Greece (2010-2014) : privatization and rationing
View/ Open
Keywords
Πολιτική περιοριστικής διανομής ; Συστήματα Λογαριασμών Υγείας (ΣΛΥ) ; Φαρμακευτικές δαπάνες ; Ιδιωτικοποίηση φαρμακευτικής περίθαλψης ; Φαρμακευτική πολιτική ; Rationing ; System Health Accounts (SHA) ; Pharmaceutical expenditure ; Privatization of pharmaceutical care ; Pharmaceutical policiesAbstract
Greece in recent years due to the economic crisis has implemented austerity policies in all areas. The health sector was not excluded from them. In this paper an attempt was made to study all the measures taken by the State and related to pharmaceutical expenditure, directly or indirectly, in the years 2010-2014 and evaluated on two features to determine whether pharmaceutical care is privatized. The first feature is, when they are related categories of expenditure, if these measures pass on the financial burden to the financial institution HF3 ie "Households" – Consumer, as described by the System Health Account. The second characteristic is whether these measures constitute Rationing, ie what "Area" are classified, by Redwood, "White", "Grey" or "Black". In total collected 136 Laws and Ministerial Decisions include measures relating to pharmaceutical expenditure. Of these, 105 measures relate to categories of expenditure and show a change in financial fund and 137 show rankings in the "Area": "White", "Grey" and "Black". The results showed that 93% of the measures concerning the categories of expenditure shift the financial burden to the "Households" - Consumers. While 50% of the measures were classified as to feature Rationing belong to the "Grey Area" - Unearmarked measures. Indeed, in 2013 and 2014, measures under the "Grey area" reaches 54% and 64% respectively and when a large number of measures seen in "Grey" and "Black Area" indicates privatization of the health system. It so relatively safely be said that the pharmaceutical care is in the privatization process.